Medical Organ Preservation Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Organ Preservation Devices
1.1 - About Medical Organ Preservation Devices sector
Companies in the Medical Organ Preservation Devices category design and manufacture systems that sustain donor organs ex vivo during storage and transport, optimizing viability prior to transplantation. These vendors deliver portable perfusion platforms, monitoring capabilities, and validated preservation workflows that extend safe time windows and enable longer-distance logistics. M&A analysts seeking strategic buyers in this category evaluate providers of integrated hardware, disposables, and software that improve transplant readiness.
Offerings typically include hypothermic and normothermic machine perfusion systems for heart, lung, liver, kidney, and pancreas, with integrated oxygenation, temperature control, and hemodynamic monitoring. Vendors provide sterile single-use perfusion circuits, preservation solutions and perfusates, validated organ transport containers, and bedside or cloud data logging and telemetry. Many also deliver workflow software, QA tools, training, and field service to standardize protocols, document compliance, and support decision-making on organ viability.
Primary customers include hospital transplant programs, organ procurement organizations, and academic medical centers conducting transplant R&D. These solutions help reduce organ discard rates, extend preservation time to expand the donor pool, improve graft function and recipient outcomes, and streamline logistics and documentation for regulatory audits. Buyers also gain consistent, data-driven viability assessment, facilitating broader geographic matching and more predictable operating schedules.
2. Buyers in the Medical Organ Preservation Devices sector
2.1 Top strategic acquirers of Medical Organ Preservation Devices companies
TransMedics
- Description: Provider of medical technology and logistics solutions for organ transplantation, offering its FDA-approved Organ Care System (OCS) platforms and nationwide National OCS Program to keep donor organs functioning, assess viability in real time, and streamline retrieval and transport, thereby expanding access to usable organs and increasing transplant volumes.
- Key Products:
- OCS Heart: OCS Heart preserves and transports donor hearts in a warm, functioning state, maintaining viability and perfusion to increase successful heart transplant opportunities and outcomes
- OCS Lung: OCS Lung keeps donor lungs alive and functioning while enabling clinical assessment during transport, improving graft quality and post-transplant results for recipients
- OCS Liver: OCS Liver provides normothermic perfusion and monitoring of donor livers during transit, reducing ischemic injury and enhancing transplant success and organ utilization
- Services and Support: TransMedics supplies training, technical assistance and logistics coordination that integrates OCS devices into hospital workflows, ensuring reliable operation, compliance and streamlined transplant procedures
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Organ Preservation Devices sector
M&A buyer group 1: Transplant Medicine
CareDx
- Type: N/A
- Employees: ●●●●●
- Description: Provider of non-invasive, genomics-based diagnostic and surveillance solutions that measure donor-derived cell-free DNA and gene expression to manage organ transplant patients, offering blood tests and HLA typing tools to detect allograft injury, monitor rejection risk and improve transplant outcomes.
- Key Products:
- AlloSure: Non-invasive NGS blood test quantifies donor-derived cell-free DNA to detect kidney allograft injury and active rejection with higher accuracy than serum creatinine
- AlloMap: Gene-expression blood test analyzes 20 genes to identify heart transplant patients with low risk of moderate/severe acute cellular rejection, guiding biopsy decisions
- AlloSure Lung: Surveillance assay for lung transplants prognoses chronic lung allograft dysfunction, detects acute cellular rejection onset and monitors treatment response
- HeartCare: Integrated AlloSure and AlloMap Heart monitoring program enabling early heart transplant surveillance, delivering comparable five-year outcomes while significantly reducing redundant biopsies.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Organ Preservation Devices sector
3.1 - Buyout funds in the Medical Organ Preservation Devices sector
2.2 - Strategic buyer groups for Medical Organ Preservation Devices sector
4 - Top valuation comps for Medical Organ Preservation Devices companies
4.2 - Public trading comparable groups for Medical Organ Preservation Devices sector
Valuation benchmark group 1: Cardiovascular and Electrophysiology Device Manufacturers
Boston Scientific
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medical solutions, developing and manufacturing medical devices for interventional medical specialties including cardiology, oncology, endoscopy, and neuromodulation, aimed at improving patient health and transforming lives worldwide.
- Key Products:
- Cardiac Devices: Devices for diagnosing and treating heart conditions including stents, pacemakers, and defibrillators
- Oncology Solutions: Minimally invasive medical devices for diagnosing and treating various cancers
- Endoscopy Devices: Tools for diagnosing and treating gastrointestinal and pulmonary conditions
- Neuromodulation Devices: Electronic implantable technologies for managing chronic pain and neurological disorders
- Peripheral Intervention Devices: Technologies for treating peripheral artery and vein conditions.